<DOC>
	<DOCNO>NCT00976209</DOCNO>
	<brief_summary>This randomize , two-way crossover , multicenter study evaluate consumer preference Phenylephrine Extended Release Tablets , 30 mg take one tablet every 12 hour , Phenylephrine Immediate Release Tablets , 10 mg take one tablet every 4 hour subject least mild allergic rhinitis nasal congestion . Approximately 250 participant complete questionnaire take one test product 3 day follow 3 day ( ± 1 day ) washout period ; take alternate test product 3 day . Analysis product consumer prefer , , product convenient , , evaluate .</brief_summary>
	<brief_title>Consumer Preference Study Two Formulations Phenylephrine Hydrochloride ( Study CL2008-15 ) ( P07530 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Rhinitis , Vasomotor</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<criteria>Healthy male female volunteer must 18 year old . Participants must willing stop use current decongestant allergy medication study , start runin period ( Visit 2 ) . Participants must document history allergic rhinitis cause ragweed allergen least prior two year . Participants must document skin test ( prick wheal &gt; = 3 mm large diluent intradermal wheal &gt; =7 mm large diluent control ) positive vitro test specific IgE ragweed allergen within last four year . Participants must sign clinical evaluation symptom nasal congestion least mild severity ( sign/symptom clearly present , minimal awareness ; easily tolerate ) Visit 3 follow runin period visit 5 follow washout period . Clinical laboratory test ( complete hematology , blood chemistry , urinalysis ) must within normal limit clinically acceptable Investigator/Sponsor . Sponsor grant waiver . Participants must seat ( 5 minute rest ) systolic/diastolic blood pressure ≤ 138/88 mmHg . Participants must normal clinically acceptable physical exam electrocardiogram ( ECG ) 12lead ECG ( record 25 mm/s ) . Participants must free clinically significant disease require physician 's care and/or would interfere study evaluation , procedure participation . Participants must agree take monoamine oxidase inhibitor ( MAOI ) 14 day study participation 14 day end study . Participants must willing give write informed consent ( prior study relate procedure perform ) able adhere restriction examination schedule . Female participant childbearing potential ( nonmenopausal female hysterectomy , bilateral oophorectomy , medically document ovarian failure , include young woman yet start menstruate ) must use medically acceptable ( documented failure rate le 1 % ) birth control measure . Examples medically acceptable contraception include hormonal contraceptive , intrauterine device ( IUD ) , doublebarrier method ( combination male female condom , diaphragm , spermicidal gel , sponge ) sterilization . Participants must able read write English , must understand dose schedule . Participants must significant medical condition , judgment investigator , contraindication use phenylephrine HCl , might interfere study require treatment expect affect blood pressure . These may include thyroid disease ( e.g . hyperthyroidism , hypothyroidism ) , uncontrolled diabetes mellitus , coronary heart disease , ischemic heart disease , elevate intraocular pressure , prostatic hypertrophy , etc . Participants receive allergen immunotherapy Xolair ( omalizumab ) therapy within past two year . Participants history clinically significant local systemic infectious disease within four week prior initial treatment administration . Participants participate clinical trial investigational treatment within 30 day prior start study ( Runin Period Day 1 ) . Participants , appear , know , current former addict alcoholic . Participants know allergy intolerance phenylephrine HCl , decongestant , loratadine , desloratadine antihistamine . Females pregnant , nurse unwilling use/practice medically acceptable contraception ( documented failure rate le 1 % ) . Participants history asthma , rhinitis medicamentosa , acute chronic sinusitis . Participants use use inhale , oral , rectal , topical , intramuscular , and/or intravenous potent chronic intermittent corticosteroid ( 1 % topical hydrocortisone permit ) . Participants work study site and/or Investigator family member study staff and/or Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>